{"doi":"10.5603/ocp.2018.0040","title":"Nivolumab in the treatment of advanced renal cell carcinoma","abstract":null,"journal":"Oncology in Clinical Practice","year":2019,"id":605853,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1555026,"name":"Zuzanna Synowiec","orcid":null,"position":1,"is_corresponding":false},{"id":1555025,"name":"Piotr Tomczak","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Nivolumab in the treatment of advanced renal cell carcinoma","abstract":"Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody approved for the treatment of advanced and metastatic renal cell carcinoma. Treatment with nivolumab is characterised by favourable toxicity profile. The occurrence of grade 3 and 4 toxicity during the therapy is low. This article describes a medical history of a patient with metastatic renal cell carcinoma treated with nivolumab.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W2955056171","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.10141701,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://journals.viamedica.pl/oncology_in_clinical_practice/article/download/OCP.2018.0040/48347","host_type":"journal"},{"url":"https://journals.viamedica.pl/oncology_in_clinical_practice/article/download/OCP.2018.0040/48347","host_type":"publisher"},{"url":"https://journals.viamedica.pl/oncology_in_clinical_practice/article/viewFile/60485/48347","host_type":"publisher"},{"url":"https://doi.org/10.5603/ocp.2018.0040","host_type":"journal"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Renal cell carcinoma treatment","Economic and Financial Impacts of Cancer"],"mesh_terms":[],"keywords":["Nivolumab","Medicine","Renal cell carcinoma","Toxicity","Oncology","Internal medicine","Carcinoma","Antibody","Immunotherapy","Cancer","Immunology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T03:24:01.259307Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}